FDA Adverse Event Injury Summary report: N

UNKNOWN BMD WOMENS HEALTH MESH PRODUCT

MDR report key: 8921760 · Received August 22, 2019

Report

Report Number
1018233-2019-04987
Event Type
Injury
Date Received
August 22, 2019
Report Date
August 26, 2019
Manufacturer
C.R. BARD, INC. (COVINGTON) -1018233
Product Code
FTL
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

CORRECTION: B7 H11:SECTION A THROUGH F - THE INFORMATION PROVIDED BY BD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BD.

Additional Manufacturer Narrative · 1

THE SAMPLE WAS NOT RETURNED. THE LOT NUMBER IS UNKNOWN; THEREFORE, THE DEVICE HISTORY RECORD COULD NOT BE REVIEWED. THE INSTRUCTIONS FOR USE WHICH ACCOMPANIES ALL DEVICES CURRENTLY ADDRESSES POTENTIAL RISKS ASSOCIATED WITH SURGICALLY IMPLANTED MATERIALS. THE INSTRUCTIONS FOR USE STATES IN THE ADVERSE EVENTS: ¿THE PRODUCT FAMILY FOR THIS WOMEN¿S HEALTHCARE PRODUCT IS UNKNOWN. THEREFORE, BARD IS UNABLE TO DETERMINE THE ASSOCIATED LABELING AND DFMEA TO REVIEW. ALTHOUGH THE PRODUCT FAMILY IS UNKNOWN, THE WOMEN¿S HEALTH PRODUCT IFUS ARE FOUND TO BE ADEQUATE BASED ON PAST REVIEWS." (B)(4).

Description of Event or Problem · 1

IT WAS REPORTED IN THE PATIENT¿S MEDICAL RECORDS THAT AS A RESULT OF HAVING THE PRODUCT IMPLANTED, THE PATIENT HAS EXPERIENCED ABDOMINAL ADHESIVE DISEASE, ABDOMINAL FOREIGN BODY (PREVIOUS GORE-TEX SACROCOLPOPEXY), RECURRENT CERVICAL STUMP PROLAPSE, CYSTOCELE, RECTOCELE, ENTEROCELE, URETHROVESICAL JUNCTION HYPERMOBILITY, STRESS URINARY INCONTINENCE AND REQUIRED ONE SURGICAL INTERVENTION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
717469 UNKNOWN BMD WOMENS HEALTH MESH PRODUCT UNKNOWN BMD WOMEN¿S HEALTH MESH PRODUCT FTL C.R. BARD, INC. (COVINGTON) -1018233 UNK

Patients

Seq Age Sex Outcome Treatment
1 47 YR Required Intervention GORTEX MYCROMESH| GORTEX MYCROMESH